DRUG PROFILE FORM

1. DRUG NAME Pantoprazole IV
PHARMACOLOGICAL
CLASS
Proton pump inhibitors
THERAPEUTIC
CLASS
Gastric acid suppressant
INDICATIONS In treatment for GERD , Erosive esophagitis , Zollinger-Ellision syndrome
DRUG PREGNANCY
CATEGORY
A B C D X

TERATOGENIC EFFECT No significant teratogenic effect is reported.
DOSAGE
(AS PER BNF)
ADULT GERIATRIC
PREGNA
NCY
RENAL
IMP.
HEPATIC IMP.
40 mg 20 - 40mg 20 - 40mg 20 - 40mg 20 - 40mg
ADMINISTRATION
INFORMATION
Drug should be taken 30 mins before a meal.
Do not crush , chew or break the tablet , take it as a whole.
ADMINISTRATION
PRECAUTION
Acute interstitial nephritis may occur at any point in patient during PPI
therapy and it is generally due to idiopathic hypersensitivity reaction.
LETHAl / FATAL DOSE 798mg/kg
PREFERRED TIME OF
DRUG ADMINISTRATION
AND REASON
Pan should be taken once daily in the morning.
PHARMACOKINETICS
ORAL
BA
PROTEI
N
BINDIN
G
METABOLIS
M
T1/2 EXCRETION
77% 98%
In liver
through CPY
System
1 hr
71% in urine
18% in feces
No renal
excretion

2. PHARMACODYNAMICS /
MOA
Inhibits the action of PPI by binding to hydrogen-potassium adenosine
triphosphate,located at the parietal cells and there by suppress the secretion
of gastric acid.
CONTRAINDICATION IN
YES/NO
PEDIATRIC GERIATRIC PREGNANCY LACTATION RI HI
- - - - - -
REASON OF
CONTRAINDICATION - - - - - -
MAJOR DRUG
INTERACTIONS
Drug 1 Drug 2 Drug 3 Drug 4 Drug 5
NAME OF THE DRUG(S) Atazanavir Ceritinib
Dipyridamo
le
Ketoconazol
e
Methotrexate
EFFECT OF INTERACTIONS Severe Moderate Moderate Moderate Severe
MANAGEMENT
Avoid or
adjust the
dose
Change
the
frequency
of the
drug
Change the
frequency of
the drug
Change the
frequency of
the drug
Avoid or adjust
the dose
ADVERSE DRUG
REACTIONS (ADRS)
MILD MODERATE SEVERE
Confusion
Depression
Malaise
Vision disorder
Peripheral odema
Agranulocytosis
Hallucination
Gynaecomastia
ADDITIONAL
INFORMATION/
PRECAUTIONS OF ADRs
Monitoring liver
function in hepatic
disorder
Patient at risk of
osteoporosis
should maintain a
adequate intake of
Ca and Vitamin D
Monitor Complete blood count
in patients.
PREFERRED DURATION
(MIN-MAX) &
DESCRIPTION
Pan can be administered for maximum 2 months.
THERAPY TERMINATION
PROCEDURE
Terminate medication unless any side effects is seen in the patient.
ALTERING LABORATORY
PARAMETERS
Electrolytes – Potassium , magnesium ; Urine test

3. OVER DOSE / POISON’S
SYMPTOMS & EFFECT
Hypoactivity , ataxia , hunched sitting , limb splay , absence of ear reflex and
tremor.
MANAGEMENT OF
OVER DOSE
Discontinue the drug and give patient supportive care.